by
Motahareh Nazari, Keyvan Alavi
Manganese-Functionalized GelMA Hydrogels for MRI-Guided Immunotheranostics in Precision Oncology
Review outlines how these materials combine diagnosis, localized therapy, and immune modulation in one platform.
abstract
click to expand
Precision oncology requires multifunctional platforms capable of integrating accurate tumor diagnosis, localized therapeutic delivery, immune modulation, and real-time monitoring of treatment response. Gelatin methacryloyl (GelMA) hydrogels have emerged as versatile biomaterials for biomedical engineering because of their biocompatibility, extracellular matrix-like structure, tunable mechanical properties, photocrosslinkability, and capacity to incorporate therapeutic agents, imaging probes, and functional nanomaterials. In parallel, manganese-based materials have gained increasing attention as promising alternatives to gadolinium-based magnetic resonance imaging contrast agents and as therapeutic components capable of modulating the tumor microenvironment. Manganese ions and manganese-based nanomaterials can enhance T1-weighted MRI contrast, generate reactive oxygen species, relieve tumor hypoxia, deplete glutathione, promote immunogenic cell death, and activate the cyclic GMP-AMP synthase-Stimulator of Interferon Genes pathway. The integration of manganese-based systems with GelMA hydrogels offers a promising strategy for developing localized, stimuli-responsive, and MRI-guided immunotheranostic platforms. This review summarizes the fundamental properties of GelMA hydrogels, the diagnostic and therapeutic roles of manganese-based materials, strategies for constructing manganese-functionalized GelMA systems, and their potential applications in precision oncology. Current challenges, including manganese-associated toxicity, controlled ion release, mechanical optimization, reproducibility, and clinical translation, are also discussed. Finally, future directions are proposed for the rational design of safe, scalable, and personalized manganese-functionalized GelMA platforms for cancer diagnosis and therapy.